Ligand Pharma (LGND) Tops Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 --0%
Revenue Growth %: -32.2%
Financial Fact:
Interest expense: -3.12M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -32.2%
Financial Fact:
Interest expense: -3.12M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $0.62, $0.03 better than the analyst estimate of $0.59. Revenue for the quarter came in at $21.6 million versus the consensus estimate of $23.13 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi turns more bullish on trucking stocks
- Guggenheim Reiterates Buy Rating on Oracle (ORCL)
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
